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Abstract
Multidrug-resistant (MDR) - and extensively drug-resistant (XDR) - forms of tuberculosis are growing public health problems. Mathema-
tical models predict that the future of the MDR and XDR tuberculosis epidemics depends in part on the competitive ﬁtness of
drug-resistant strains. Here, recent experimental and molecular epidemiological data that illustrate how heterogeneity among drug-resis-
tant strains of Mycobacterium tuberculosis can inﬂuence the relative ﬁtness and transmission of this pathogen are reviewed.
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Drug resistance has become a problem of global propor-
tions, with major consequences for public health and the
world economy [1]. In Mycobacterium tuberculosis, the emer-
gence of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) strains is threatening to make one of the
most important infectious diseases untreatable [2]. MDR
strains of M. tuberculosis are deﬁned as resistant to at least
isoniazid and rifampicin, the two most potent ﬁrst-line tuber-
culosis drugs. XDR strains of M. tuberculosis are MDR strains
with additional resistance to ﬂuoroquinolones and to at least
one of the three injectable second-line tuberculosis drugs.
Recent reports of XDR tuberculosis from KwaZulu-Natal in
South Africa have illustrated the dramatic negative impact
that drug-resistant tuberculosis can have on patient survival,
particularly in areas with high rates of human immunodeﬁ-
ciency virus co-infection [3].
Understanding the ecology of drug-resistant pathogens is
essential for devising rational programmes to preserve the
effective lifespan of antimicrobial agents and to abrogate epi-
demics of drug-resistant organisms. Studies in model organ-
isms have shown that drug resistance is often associated
with a ﬁtness cost (i.e. reduced growth rate in the absence
of the drug) [4]. However, particular drug resistance-confer-
ring mutations can have a variable impact on bacterial ﬁtness,
which varies according to the speciﬁc resistance-conferring
mutation and strain genetic background. Furthermore, com-
pensatory evolution can reduce initial ﬁtness defects caused
by particular drug resistance-conferring mutations [5]. In
M. tuberculosis, mathematical models predict that the future
of MDR tuberculosis epidemics will be inﬂuenced by strain
ﬁtness [6,7]. However, empirical data are lacking. We have
used a combination of in vitro ﬁtness assays and molecular
epidemiological studies to investigate the effect of bacterial
genetics on the competitive ﬁtness and relative transmission
of drug-resistant M. tuberculosis.
To study the inﬂuence of different rifampicin resistance-
conferring mutations on the ﬁtness of rifampicin-resistant
strains of M. tuberculosis, we selected for spontaneous rpoB
mutants in vitro using two different pan-susceptible parental
strains [8]. We performed competitive ﬁtness experiments
in vitro, and found that in these laboratory-derived mutants,
rifampicin resistance was universally associated with a com-
petitive ﬁtness cost (Fig. 1). However, the magnitude of this
defect was determined by the speciﬁc resistance mutation
and strain genetic background. For example, whereas the
rpoB S531L mutant had higher competitive ability than other
mutants in both strain backgrounds, the rpoB H526D muta-
tion had a different ﬁtness effect in the two strain back-
grounds. Interestingly, when we compared clinical strains of
M. tuberculosis that had acquired rifampicin resistance during
patient treatment, we found that four out of ﬁve clinical
strains with the rpoB S531L mutations had no ﬁtness cost as
compared to the initial rifampicin-susceptible isolate recov-
ered from the same patient (Fig. 2). This suggests that either
the rpoB S531L change caused no ﬁtness defect in these par-
ticular strain backgrounds, or that the low initial ﬁtness
costs associated with the rpoB S531L mutation were miti-
gated by compensatory evolution during prolonged patient
treatment. Importantly, rpoB S531L, the mutation associated
with the lowest ﬁtness cost in the laboratory mutants and
no ﬁtness cost in some clinical strains, was also the most
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frequent rifampicin resistance mutation among clinical iso-
lates globally. By contrast, the rpoB R529Q mutant, which
carried the highest ﬁtness cost of all mutants, has never
been observed in clinical settings.
In a second study, we investigated the role of different
isoniazid resistance-conferring mutations on the transmission
of isoniazid-resistant M. tuberculosis [9]. Isoniazid is a prodrug
that needs to be activated to its bioactive form by the myco-
bacterial katalase-peroxidase encoded by katG [10]. Dele-
tions or missense mutations in katG generally lead to
isoniazid resistance by disabling drug activation. Because katG
helps to protect the mycobacterial cell against host-mediated
oxidative stress, strains with disrupted katG suffer virulence
defects in animal models. However, one particular katG
mutation, S315T, is associated with a high degree of isoniazid
resistance but retains enzyme activity and virulence in mice
[11]. Using a population-based molecular epidemiological
approach, we measured the relative transmission of isonia-
zid-resistant strains of M. tuberculosis harbouring different
katG mutations in San Francisco during a 9-year period [9].
We found that only strains with the katG S315T mutation or
mutations outside of katG were associated with successful
transmission. In contrast, strains with isoniazid resistance-
conferring mutations likely to abrogate katG activity did not
cause one secondary case during the whole study period.
These results were consistent with the experimental evi-
dence reviewed above, and further demonstrate that in
M. tuberculosis, different drug resistance-conferring mutations
can have variable effects on strain ﬁtness and transmission.
M. tuberculosis has a phylogeographic population structure,
with different strain lineages being associated with different
geographical regions [12,13]. When we compared the distri-
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Fig. 1. Relative competitive ﬁtness of laboratory-derived rifampicin-resistant mutants of Mycobacterium tuberculosis. The relative ﬁtness of the rif-
ampicin-susceptible ancestor is deﬁned as 1 (black line). All rifampicin-resistant mutants had a statistically signiﬁcant ﬁtness cost as compared to
the rifampicin-susceptible ancestor strain (error bars indicate 95% CIs). This cost was less in rpoB S531L mutants than in other rpoB mutants,
irrespective of the strain background. Light grey bars, CDC1551 mutants; dark grey bars, T85 mutants.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1 2 3 4 5 6 7 8 9 10
Isolate pair
M
ea
n 
re
la
tiv
e 
fit
ne
ss
Fig. 2. Relative competitive ﬁtness of clinically derived rifampicin-resistant mutants of Mycobacterium tuberculosis. Four of the ﬁve mutants with
the rpoB S531L mutation (hatched bars) had no ﬁtness cost as compared with their rifampicin-susceptible ancestors. All mutants with other rpoB
mutations (black bars) had signiﬁcant ﬁtness defects (error bars indicate 95% CIs).
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bution of strain lineages in the isoniazid-resistant strains from
San Francisco, we found statistically signiﬁcant associations
among the three strain lineages that dominate in San Fran-
cisco and three groups of isoniazid resistance-conferring
mutations (Table 1). The ‘Beijing’ lineage was associated with
katG mutations other than S315T, which were likely to abro-
gate katG activity. The inhA promoter mutation, also associ-
ated with isoniazid resistance, occurred signiﬁcantly more
frequently among the ‘ancestral’ lineage, and the ‘Euro-Amer-
ican’ lineage was associated with the katG S315T mutation,
which maintains katG activity. These associations suggest that
genetic differences between the strain lineages could inﬂu-
ence their propensity to have different isoniazid resistance-
conferring mutations. In particular, the association of the
‘Beijing’ strains with ‘costly’ katG mutations is intriguing, as it
suggests that this strain lineage might be less susceptible to
host-mediated oxidative stress. Alternatively, ‘Beijing’ strains
might be better adapted to compensate for the loss, or
reduced activity, of katG in the context of isoniazid resis-
tance. As a consequence of either of these scenarios, ‘Beijing’
strains with low-cost isoniazid resistance-conferring muta-
tions such as katG S315T may be particularly ﬁt. In support
of this possibility, ‘Beijing’ strains have been associated with
resistance to isoniazid in several geographical areas [14].
Taken together, the data from these two studies show
that there is a strong selection for drug resistance-conferring
mutations associated with low ﬁtness cost in tuberculosis
patients, and that bacterial genetics can impact on the ﬁtness
and transmissibility of drug-resistant M. tuberculosis. Our ﬁnd-
ings have implications for predicting the future of the MDR
and XDR tuberculosis epidemic.
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Table 1. Association between three Mycobacterium
tuberculosis strain lineages and three classes of isoniazid
resistance-conferring mutations
Mutation
Beijing
lineage
(N = 36)
n (%)
Ancestral
lineage
(N = 45)
n (%)
Euro-American
lineage
(N = 61)
n (%)
OR
(95% CI)a p
katG mutations
other than S315T
15 (41.7) 2 (4.4) 10 (16.4) 5.6 (2.1–15.1) <0.001
katG S315T 13 (36.1) 15 (33.3) 31 (50.8) 2.0 (0.94–4.1) 0.0517
inhA promoter –15;c-t 5 (13.9) 21 (46.7) 13 (21.3) 3.8 (1.6–9.0) <0.001
No/other mutation 3 (8.3) 7 (15.6) 7 (11.5)
aFor each lineage, the v2 test was used to compare the proportion of the most
frequent mutation with its proportion in the two other lineages combined.
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